Clene Inc. Advances Toward FDA Submission for ALS Therapy with Strong Q2 2025 Results

Clene Inc. (NASDAQ: CLNN), a biopharmaceutical company at the forefront of developing treatments for neurodegenerative diseases, has announced its financial results for the second quarter of 2025, alongside significant progress in its lead candidate, CNM-Au8, for amyotrophic lateral sclerosis (ALS). The company has confirmed it has sufficient cash reserves to fund operations into the first quarter of 2026, ensuring the continuity of its research and development efforts.

The focus of Clene's upcoming discussions with the FDA will center on survival data from CNM-Au8's clinical trials, a critical step toward securing approval under the FDA's accelerated pathway for ALS treatments. Additionally, the company is preparing to analyze neurofilament light biomarker data from the NIH-sponsored Expanded Access Program, with results anticipated in the fourth quarter of 2025. These analyses are pivotal for supporting the potential New Drug Application (NDA) submission by the end of the year.

ALS, a progressive neurodegenerative disease, currently has limited treatment options, making Clene's CNM-Au8 a beacon of hope for patients and families affected by the condition. The therapy's novel mechanism, which targets mitochondrial function and the NAD pathway while reducing oxidative stress, represents a significant advancement in the field. For more information on Clene's innovative approach to treating neurodegenerative diseases, visit https://www.clene.com.

The company's commitment to delivering an impactful therapy to the ALS community underscores the importance of its current milestones. With the planned FDA meeting and the forthcoming biomarker data analysis, Clene is on a clear path toward making a meaningful difference in the lives of those battling ALS. The potential approval of CNM-Au8 could mark a turning point in the treatment of this devastating disease, offering new hope where options are currently scarce.